These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Metabolic modulation: a new therapeutic target in treatment of heart failure. Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344 [TBL] [Abstract][Full Text] [Related]
6. Metabolic agents in the management of diabetic coronary patients: a new era. Marazzi G; Volterrani M; Rosano GM Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501 [TBL] [Abstract][Full Text] [Related]
7. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease? Rizzon P; Iliceto S; Marangelli V Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732 [No Abstract] [Full Text] [Related]
8. [Therapeutic application of myocardial cytoprotection]. Ribeiro C Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940 [No Abstract] [Full Text] [Related]
9. Myocardial metabolic manipulation: a new therapeutic approach in heart failure? O'Meara E; McMurray JJ Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211 [TBL] [Abstract][Full Text] [Related]
10. Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion. Wambolt RB; Henning SL; English DR; Bondy GP; Allard MF J Mol Cell Cardiol; 1997 Mar; 29(3):939-48. PubMed ID: 9152855 [TBL] [Abstract][Full Text] [Related]
11. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Rosano GM; Vitale C; Fragasso G Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201 [TBL] [Abstract][Full Text] [Related]
12. Trimetazidine in the myocardial cell mechanisms of cytoprotection. Labrid C Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510 [TBL] [Abstract][Full Text] [Related]
13. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Rupp H; Zarain-Herzberg A; Maisch B Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634 [TBL] [Abstract][Full Text] [Related]
15. [Post-infarct myocardial remodelling: from experimental data to the prevention of heart failure]. Jalil JE; Corbalán R Rev Med Chil; 1990 Oct; 118(10):1143-9. PubMed ID: 2152634 [TBL] [Abstract][Full Text] [Related]
16. Modification of myocardial substrate use as a therapy for heart failure. Abozguia K; Clarke K; Lee L; Frenneaux M Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):490-8. PubMed ID: 16932766 [TBL] [Abstract][Full Text] [Related]
17. Role of trimetazidine in management of ischemic cardiomyopathy. Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202 [TBL] [Abstract][Full Text] [Related]
18. Chronic angina: new medical options for treatment. McCullough PA Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688 [TBL] [Abstract][Full Text] [Related]